TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1706015
Drug: Diuretic (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic (25 mg hydrochlorothiazide and 50 mg triamterene)
Study: 6785336
Drug: Long-term chrysotherapy
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term chrysotherapy (gold therapy)
Study: 29183324
Drug: Bar (565
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bar (565 kJ, 7.5 g EAAs, 40% L-leucine)
Study: 29183324
Drug: Gel (477
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel (477 kJ, 7.5 g EAAs, 40% L-leucine)
Study: 17032712
Drug: Calcitriol 0.25
Normalized name: CALCITRIOL 0.25MCG CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitriol 0.25 mug twice a day
Study: 8589000
Drug: G‐CSF (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF (5 micrograms/kg/day)
Study: 31410778
Drug: Experimental hyperbaric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental hyperbaric oxygen therapy
Study: 22779693
Drug: Alosetron 0.5
Normalized name: alosetron 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alosetron 0.5 mg QD
Study: 22779693
Drug: Alosetron 1
Normalized name: alosetron 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alosetron 1 mg BID
Study: 22779693
Drug: Alosetron (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alosetron (all doses)
Study: 17209192
Drug: Placebo (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0 mg gluten)
Study: 17209192
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg gluten
Study: 9389816
Drug: Nafarelin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nafarelin (200 micrograms twice daily)
Study: 8077329
Drug: LHRHa (deslorelin)
Normalized name: ALARELIN ACETATE 800 ug in 1 mg INTRAMUSCULAR INJECTION, POWDER, FOR SUSPENSION [LHRHa]
Approvals — FDA: no, EMA: no, PMDA: no
Description: LHRHa (deslorelin) administered sc at a dose of 4 micrograms/kg.day for a period of 4 yr
Study: 29378703
Drug: Ceftazidime 50
Normalized name: ceftazidime 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime 50 mg/kg twice daily
Study: 29378703
Drug: Ceftazidime 25
Normalized name: ceftazidime 250 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime 25 mg/kg every 8 hours (q8h)
Study: 29378703
Drug: Ceftazidime 50
Normalized name: ceftazidime 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime 50 mg/kg every 8 hours (q8h)
Study: 27603346
Drug: S-1 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 plus cisplatin with concurrent radiotherapy (SCCCR)
Study: 27603346
Drug: Cisplatin alone
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin alone with concurrent radiotherapy (CCCR)
Study: 24922488
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of TAU and neurofeedback (n = 45)
Study: 24922488
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU) (n = 26)
Study: 18617079
Drug: 2 weeks
Normalized name: Rykindo, 25 mg/2 weeks intramuscular powder for injection, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 weeks of nicotine patches
Study: 18617079
Drug: 8 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8 weeks of nicotine patches
Study: 12297208
Drug: Norsteroid supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norsteroid supplementation (224 mg of 19‐nor‐4‐androstene‐3,17‐dione and 120 mg of 19‐nor‐4‐androstene‐3,17‐diol, total daily dose = 344 mg) for 8 weeks
Study: 7570331
Drug: Intravenous cefotaxime
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cefotaxime 2 gm
Study: 2229793
Drug: Procainamide (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procainamide (12 to 15 mg/kg body weight)
Study: 2229793
Drug: Propafenone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone (1 to 2 mg/kg)
Study: 28370947
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) for 6 weeks
Study: 19725251
Drug: Donepezil 5
Normalized name: donepezil 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil 5 mg taken once daily for approximately 17 days
Study: 11343043
Drug: Iron supplements,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplements, 1 mg/kg/d from 4 to 9 months
Study: 11343043
Drug: Iron supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplements from 6 to 9 months
Study: 9625273
Drug: Grapefruit juice
Normalized name: grapefruit juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grapefruit juice (250 ml) with oral diazepam (5 mg)
Study: 2843130
Drug: GS +
Normalized name: GS 0573
DrugBank: GS 0573 (DB08843)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GS + mitomycin C (MMC) 10 mg + adriamycin (ADR) 20 mg (group A, n = 45)
Study: 2843130
Drug: GS +
Normalized name: GS 0573
DrugBank: GS 0573 (DB08843)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GS + MMC 10 mg + ADR 20 mg + 200 mg/day of oral 5‐fluorouracil (5‐FU) (group B, n = 36)
Study: 2843130
Drug: GS +
Normalized name: GS 0573
DrugBank: GS 0573 (DB08843)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GS + 200 mg/day of 5‐FU (group C, n = 31)
Study: 29297260
Drug: MFGM (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: MFGM (1 g/day) with light gymnastic exercise
Study: 22225628
Drug: Psychotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotherapy plus treatment as usual (P + TAU)
Study: 20358002
Drug: Rebamipide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rebamipide (100 mg t.i.d.)
Study: 20358002
Drug: Famotidine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine (20 mg b.i.d.)
Study: 9661593
Drug: Urinary N-telopeptide
Normalized name: N-ethylurea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urinary N-telopeptide of type I collagen (NTx) excretion
Study: 8310510
Drug: rh‐SOD (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: rh‐SOD (200 mg intravenously during surgery)
Study: 31606257
Drug: Isopropyl alcohol/organofunctional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isopropyl alcohol/organofunctional silane solution (IOS) treatment
Study: 12885095
Drug: 4-aminopyridine (4-AP)
Normalized name: 4-AP
DrugBank: Dalfampridine (DB06637)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-aminopyridine (4-AP) 5 mg/day, increased by 5 mg/week to a maximum of 30 mg/day for 12 weeks
Study: 11533770
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg rectal diclofenac immediately after cesarean section followed by 50 mg at 12 hours and 100 mg at 36 hours after surgery
Study: 11533770
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no diclofenac suppositories)
Study: 29618322
Drug: Sequential probability
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential probability ratio test
Study: 27184139
Drug: Antagonist rescue
Normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antagonist rescue combined with cabergoline
Study: 27184139
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (Antagonist rescue combined with cabergoline and Cabergoline alone)
Study: 8404785
Drug: Ethyl Ester
Normalized name: Amben ethyl ester
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethyl Ester (EE) fish oil concentrate (2.2 g EPA, 1.2 g DHA)
Study: 8404785
Drug: Triglyceride (TG)
Normalized name: CAPRYLIC TRIGLYCERIDE
DrugBank: Tricaprylin (DB12176)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triglyceride (TG) fish oil concentrate (2.2 g EPA, 1.4 g DHA)
Study: 30966728
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg single-dose submucosal betamethasone
Study: 28256747
Drug: Elbasvir/Grazoprevir (EBR/GZR)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elbasvir/Grazoprevir (EBR/GZR) 50 mg/100 mg for 12 weeks
Study: 28256747
Drug: Placebo (Deferred-Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (Deferred-Treatment Group)
Study: 25877363
Drug: High condylectomy
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High condylectomy with postsurgical orthodontic therapy (group A)
Study: 25877363
Drug: High condylectomy
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High condylectomy without postsurgical orthodontic therapy (group B)
Study: 24165906
Drug: Tiotropium solution
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium solution 5 µg
Study: 24165906
Drug: Powder 18 µg
Normalized name: penicillin G 18 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powder 18 µg
Study: 10722499
Drug: Oral artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral artesunate (2 mg/kg of body weight)
Study: 9197354
Drug: Pentoxifylline 400
Normalized name: pentoxifylline 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline 400 mg p.o. t.i.d.
Study: 28639467
Drug: Gemcitabine diluted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine diluted from a concentrate for solution for infusion (CSI) containing ethanol
Study: 25427568
Drug: Multifactorial intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multifactorial intervention program including rehabilitative therapy, intake of hyperproteic nutritional shakes, memory workshop, and medication review.
Study: 23609385
Drug: Fluoxetine monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine monotherapy (10 to 80 mg daily for up to 14 weeks)
Study: 20465435
Drug: Maltitol chocolate
Normalized name: Maltitol
DrugBank: Maltitol (DB16867)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maltitol chocolate (5 to 15 g)
Study: 18469202
Drug: Body Mass
Normalized name: Total Body Massager Item
Approvals — FDA: no, EMA: no, PMDA: no
Description: Body Mass Index (BMI) and Subcutaneous Adipose Tissue (SAT)
Study: 16614984
Drug: Intraduodenal infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraduodenal infusion of 50 g of glucose in 300 mL saline (16.7%)
Study: 16614984
Drug: Intraduodenal infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraduodenal infusion of 50 g of glucose in 600 mL saline (8.3%)
Study: 16614984
Drug: Intraduodenal infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraduodenal infusion of 50 g of glucose in 1200 mL saline (4.1%)
Study: 16614984
Drug: Saline (0.9%)
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline (0.9%) infusion after glucose infusion
Study: 8635376
Drug: Inhaled salmeterol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled salmeterol, 50 microg twice a day for seven doses
Study: 1442650
Drug: Experimental reduced-protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental reduced-protein formula (13 g/L protein, whey-casein ratio 40:60, added tryptophan 490 mumol/L)
Study: 1442650
Drug: Conventional formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional formula (15 g protein/L, whey-casein ratio 60:40)
Study: 30562195
Drug: Fast-track radioiodine
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast-track radioiodine ablative therapy (RIT) 1 week after thyroidectomy
Study: 26537053
Drug: Raloxifene (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene (120 mg oral once daily)
Study: 23524843
Drug: Intensive sensory
Normalized name: SENSORY ORGANS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive sensory and motor stimulation program (16 sessions in rehabilitation center, daily sessions at home for 8 weeks)
Study: 10077966
Drug: Ethisorp patches
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethisorp patches
Study: 31983598
Drug: Verum group
Normalized name: Cinnamomum verum whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verum group (TENS therapy)
Study: 23941781
Drug: individual cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: individual cognitive therapy (CT)
Study: 23941781
Drug: interpersonal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: interpersonal therapy (IPT)
Study: 22547421
Drug: Deferred ART
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Deferred ART (defer treatment until CD4 count <350 cells/µL)
Study: 21276222
Drug: Standard Light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Light Treatment (SLT) at 10,000 lux for 30 minutes
Study: 21276222
Drug: Low-intensity Blue-enriched
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity Blue-enriched Light Treatment (BLT) at 750 lux for 30 minutes
Study: 14720270
Drug: Butterbur (BB)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butterbur (BB) 25 mg
Study: 8505831
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: 2000 mL of 5% glucose in water or saline plus 1000 mL of 5% amino acid solution per day (approximately 10 kcal/kg per day and 1 g of protein per kilogram per day)
Study: 8505831
Drug: Group C:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C: 2000 mL of 5% glucose in water or saline plus 500 mL of 5% amino acid solution and 500 mL of 10% fat emulsion (approximately 20 kcal/kg per day and 0.5 g of protein per kilogram per day)
Study: 8505831
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: 3000 mL of a 5% glucose in water or glucose in saline infusion per day (approximately 10 kcal/kg per day)
Study: 23092146
Drug: 20% carbamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% carbamide peroxide bleaching gel (Opalescence PF 20)
Study: 19904246
Drug: Esomeprazole 20-40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 20-40 mg daily
Study: 19904246
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (Esomeprazole and LARS)
Study: 18048059
Drug: Cerebrolysin (Cere)
DrugBank: Cerebrolysin (DB16599)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerebrolysin (Cere) 10 ml
Study: 18048059
Drug: Cerebrolysin (Cere)
DrugBank: Cerebrolysin (DB16599)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerebrolysin (Cere) 30 ml
Study: 15624072
Drug: PRN patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRN patients receiving RCT study medication
Study: 12584783
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment of YZM and Ritalin
Study: 7717739
Drug: Viable L
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viable L casei strain GG
Study: 7717739
Drug: Inactivated L
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated L casei strain GG
Study: 1843963
Drug: Polyethylene glycol
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyethylene glycol (PEG) solution administered at a rate of 0.5 liters daily for 8 days (Group 1: placebo first week, PEG second week)
Study: 1843963
Drug: Polyethylene glycol
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyethylene glycol (PEG) solution administered at a rate of 0.5 liters daily for 8 days (Group 2: PEG first week, placebo second week)
Study: 6754062
Drug: Vincristine 1
Normalized name: vinCRIStine 1 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vincristine 1 mg/m2, doxorubicin 40 mg/m2 on day one and cyclophosphamide 200 mg/m2 orally days 3‐6 (VAC)
Study: 6754062
Drug: Cyclophosphamide 350
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide 350 mg/m2, methotrexate 20 mg/m2, and 5‐fluorouracil 350 mg/m2 (CMF) intravenously
Study: 22301077
Drug: Antidepressant use
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant use (SSRIs and TCAs)
Study: 22301077
Drug: Depressed users
Normalized name: Malmea depressa bark extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depressed users of antidepressants
Study: 22301077
Drug: Non-depressed users
Normalized name: Malmea depressa bark extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-depressed users of antidepressants
Study: 22301077
Drug: Depressed non-users
Normalized name: Malmea depressa bark extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depressed non-users of antidepressants
Study: 18343254
Drug: Propofol 4
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol 4 mg/kg i.v. followed by infusion of 150 microg/kg x min(‐1)
Study: 8815395
Drug: High-dose thiamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose thiamine supplementation (100 mg/day)
Study: 6436874
Drug: Single night-time
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single night-time dose of trazodone (100-400 mg)
Study: 6436874
Drug: Divided daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Divided daily doses of trazodone (100-400 mg)
Study: 28853228
Drug: 200 mg/day
Normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/day Anagliptin (ANA) for 24 weeks
Study: 28853228
Drug: 200 mg/day
Normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/day Anagliptin (ANA) for 12 weeks
Study: 28853228
Drug: 25 mg/day
Normalized name: estradiol 0.025 MG/Day Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg/day Alogliptin (ALO) for 24 weeks
Study: 26458536
Drug: Combination uridine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination uridine triphosphate (UTP), cytidine monophosphate (CMP), and hydroxycobalamin (vitamin B12)
Study: 15758755
Drug: Darifenacin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darifenacin (30 mg once daily)
Study: 12724019
Drug: Metformin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin therapy (500 mg three times a day for 8 weeks)
Study: 10593775
Drug: Oxygen therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen therapy (2 L/min by nasal cannula)
Study: 10593775
Drug: Nasal CPAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal CPAP therapy (9 +/- 0.3 cm H(2)O)
Study: 8726183
Drug: Surgery followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Surgery followed by chemotherapy (29 patients)
Study: 8726183
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy followed by surgery and chemotherapy (21 patients)
Study: 31908843
Drug: Abatacept in
Normalized name: abatacept Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abatacept in combination with methotrexate
Study: 26723110
Drug: Long interval
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long interval (6 to 8 weeks) between neoadjuvant radiation therapy and surgery
Study: 26723110
Drug: Short interval
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short interval (2 weeks) between neoadjuvant radiation therapy and surgery
Study: 22267768
Drug: AZD9668 (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD9668 (60 mg twice daily orally for 4 weeks)
Study: 20874829
Drug: Astra Tech®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astra Tech® implants (n=24)
Study: 20874829
Drug: Brånemark® implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brånemark® implants (n=23)
Study: 11225459
Drug: 0.2% Lavasept
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% Lavasept solution
Study: 9311442
Drug: ACR-AQ (aclarubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACR-AQ (aclarubicin aqueous solution)
Study: 3522311
Drug: Ibuprofen 2400
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 2400 mg
Study: 25856450
Drug: Weekly or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly or biweekly visits from an educator
Study: 17087951
Drug: Adefovir dipivoxil
Normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Adefovir dipivoxil 10 mg once daily for 48 weeks, followed by adefovir dipivoxil from week 49 to 96, and then open-label for up to 240 weeks.
Study: 17087951
Drug: Adefovir dipivoxil
Normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Adefovir dipivoxil treatment for up to 240 weeks.
Study: 15008726
Drug: ProstaLund Feedback
Approvals — FDA: no, EMA: no, PMDA: no
Description: ProstaLund Feedback Treatment (PLFT) and Transurethral resection of the prostate (TURP)
Study: 11123371
Drug: TTS‐S patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: TTS‐S patch + 0.6 mg of scopolamine per os (p.o.)
Study: 11123371
Drug: TTS‐S patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: TTS‐S patch + 0.3 mg of scopolamine p.o.
Study: 11123371
Drug: TTS‐S patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: TTS‐S patch + placebo tablet
Study: 9678812
Drug: RBC 400
Normalized name: Ultratag RBC KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBC 400 mg plus clarithromycin 250 mg and tinidazole 500 mg (RBCCT)
Study: 9678812
Drug: RBC 400
Normalized name: Ultratag RBC KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBC 400 mg plus clarithromycin 500 mg and amoxycillin 1 g (RBCCA)
Study: 9678812
Drug: RBC 400
Normalized name: Ultratag RBC KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBC 400 mg plus tinidazole 500 mg and amoxycillin 1 g (RBCTA)
Study: 2645466
Drug: Immunotherapy (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy (oral bacille Calmette‐Guérin [BCG] 120 mg once a month for 5 years)
Study: 2645466
Drug: Chemoimmunotherapy (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoimmunotherapy (oral BCG 120 mg once a month for 5 years with meCCNU 130 mg/m2 on day 1 and 5-FU 325 mg/m2/day on days 1-5 and 375 mg/m2/day on days 36-40, repeated every 10 weeks for 8 cycles)
Study: 2645466
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no further therapy after surgery)